Berman Tabacco Announces Investigation of Inari Medical, Inc. (NARI) for Potential Securities Law Violations
BOSTON, Feb. 29, 2024 — Berman Tabacco, a national law firm representing investors, is investigating potential securities law violations by Inari Medical, Inc. (“Inari” or the “Company”) (NASDAQ: NARI).
About the Investigation
On February 29, 2024, before the market opened, Inari filed a Form 10-K with the Securities and Exchange Commission stating: “In December 2023, we received a civil investigative demand (‘CID’) from the U.S. Department of Justice, Civil Division, in connection with an investigation under the federal Anti-Kickback Statute and Civil False Claims Act (the ‘Investigation’). The CID requests information and documents primarily relating to meals and consulting service payments provided to health care professionals (‘HCPs’).” On February 29, 2024, shares of Inari were trading down 20% intraday.
Contact
If you have information concerning this investigation, please fill out the form on this page.
About Berman Tabacco
Since 1982, our firm has prosecuted hundreds of securities and antitrust complex cases. The firm and its attorneys have been recognized for their work on behalf of plaintiffs, including by Chambers USA, Benchmark Litigation, which has ranked the firm as Highly Recommended and a Top Ten Plaintiffs, The Legal 500, U.S. News & World Report-Best Lawyers, The Daily Journal, Lawdragon, Who’s Who Legal, and Super Lawyers.
The firm has offices in Boston, Massachusetts and San Francisco, California.
This notice may constitute attorney advertising. Past results do not guarantee future outcomes.
Contact:
Berman Tabacco
Jay Eng, Esq.
One Liberty Square
Boston, Massachusetts
(800) 516-9926
Email: law@bermantabacco.com